Dorsey & Whitney Trust CO LLC Reduces Stock Position in Danaher Co. (NYSE:DHR)

Dorsey & Whitney Trust CO LLC trimmed its position in Danaher Co. (NYSE:DHR) by 4.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,037 shares of the conglomerate’s stock after selling 423 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Danaher were worth $2,508,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Caden Capital Partners LP lifted its stake in Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after acquiring an additional 15,313 shares during the period. JARISLOWSKY FRASER Ltd raised its holdings in shares of Danaher by 10.8% during the fourth quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock worth $132,524,000 after purchasing an additional 55,908 shares during the last quarter. HighPoint Advisor Group LLC acquired a new position in Danaher during the fourth quarter valued at $2,614,000. Norden Group LLC purchased a new stake in Danaher in the first quarter valued at $4,151,000. Finally, Duality Advisers LP acquired a new stake in Danaher during the 1st quarter worth about $5,573,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $273.09 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a market cap of $197.23 billion, a PE ratio of 46.29, a price-to-earnings-growth ratio of 4.38 and a beta of 0.83. The stock’s 50 day simple moving average is $261.87 and its 200-day simple moving average is $255.96.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.05 EPS. As a group, equities research analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent research reports. Wells Fargo & Company began coverage on Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. The Goldman Sachs Group upped their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Stifel Nicolaus lifted their price objective on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, Barclays increased their target price on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Insider Buying and Selling at Danaher

In other news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,659 shares of company stock worth $11,042,433. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.